Halister News

(Bloomberg) -- Amazon sees 1Q net sales $33.3b to $35.8b, est. $36.0b (range $35.1b-$36.9b)

• Sees 1Q operating income $250m to $900m, est. $1.3b
• 4Q EPS $1.54, est. $1.36 (range 56c-$1.84)
• 4Q net sales $43.7b, est. $44.7b (range $43.5b-$45.9b)
• 4Q operating income $1.26b, est. $1.13b (range $633.0m-$1.44b)
• 4Q AWS net sales $3.54b, est. $3.61b (Bloomberg News)
• 4Q Aws net sales Growth 47%

NOTE:

• Shares down 3.2% since earnings release to $812.46 on 0.14m shares traded
• 43 buys, 5 holds, 0 sells before today
• Call 5:30pm (NY time)

Statement

(Bloomberg) -- Amgen said Repatha significantly reduced the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease in the “Fourier” Phase 3 outcomes trial.

• Repatha met primary composite endpoint and key secondary composite endpoint
• “Ebbinghaus” trial conducted in Fourier patients also met primary endpoint of showing Repatha was non- inferior to placebo for the effect on cognitive function
• AMGN will present the data March 17-18 at the American College of Cardiology meeting
• NOTE: AMGN reports 4Q results post-market; call at 5pm
• NOTE: Feb. 1, Amgen Raised at BofAML on Biosimilar Win, Repatha Data Potential

To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Catherine Larkin

--ELIZABETH FOURNIER